ASCO pre-release effect A biotechs have release extracts, pending full results later at ASCO.
All got crushed by the market and then SP bump back up a bit.
This strategy of releasing piecemeal results is just confusing the market and annoying shareholders. Adding another complexity to the matter.
Next time, just shut up and wow us.
Anyhow, because there are two stastiscal trial done - one can say that endpoint will be meet with a very level of certainty.
In other word, should ONCY replicate IND-213+Bracelet, the odds of success are in between 95 to 99%. I will let the math nerd publish their calculation here.
So, PIII appears to be cheap (2 arm) and almost a certainty if you include biomarker reading.
The market should be rewarding us a full 2$, imo just for this.
But but but, this half lingerie tactic is confusing the market.
Either you show up in full lingerie or you stay cover...